KRAS是结肠直肠癌精准医学的新目标吗?
Alice Boilève1,2,3, Cristina Smolenschi1,4, Aurélien Lambert5
1Gustave Roussy, Département de Médecine Oncologique, 94805 Villejuif, France.
Cancers
|October 26, 2024
概括
在结直肠癌 (CRC) 中准KRAS突变正在取得进展. 新的KRAS抑制剂有望改善CRC患者的治疗结果,尽管存在耐药性等挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 结肠直肠癌 (CRC) 是一个主要的全球健康问题,KRAS突变通常与预后不佳有关.
- 由于其复杂的结构,KRAS瘤基因历史上一直具有挑战性的治疗目标.
研究的目的:
- 审查对结直肠癌KRAS抑制策略的最新进展.
- 探索新兴KRAS抑制剂和组合疗法的疗效和挑战.
主要方法:
- 关于CRC中KRAS抑制剂的最近研究和临床试验的文献综述.
- 对不同类型的KRAS抑制剂 (共价,非共价) 和组合方法的分析.
主要成果:
- 克拉斯抑制剂的出现作为CRC的可行的治疗选择.
- 临床试验表明,单独或与其他药物,如抗EGFR抗体一起使用KRAS抑制剂的潜在疗效.
结论:
- 克拉斯抑制剂代表了结直肠癌治疗中的重大治疗进步.
- 目前正在进行的研究旨在克服抵抗机制和瘤异质性,以改善患者的治疗结果.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K